NASDAQ:PRLD Prelude Therapeutics Q3 2026 Earnings Results & Report $3.41 -0.04 (-1.16%) Closing price 04:00 PM EasternExtended Trading$3.32 -0.09 (-2.58%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Prelude Therapeutics missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.12 versus the $0.01 consensus estimate, while revenue of $5.65 million fell short of the $29 million estimate by $23.35 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market OpensConference Call7:00 AM ET Prelude Therapeutics EPS ResultsActual EPS-$0.12Consensus EPS $0.01Beat/MissMissed by -$0.13One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersPrelude Therapeutics Revenue ResultsActual Revenue$5.65 millionExpected Revenue$29 millionBeat/MissMissed by -$23.35 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Prelude Therapeutics Q3 2026 Earnings FAQ Did Prelude Therapeutics beat earnings estimates for Q3 2026? Prelude Therapeutics (NASDAQ:PRLD) reported earnings of -$0.12 per share for Q3 2026, missing the consensus estimate of $0.01. The report was announced on Monday, November 16, 2026. What was Prelude Therapeutics' revenue for Q3 2026? Prelude Therapeutics reported revenue of $5.65 million for Q3 2026, against a consensus estimate of $29 million. Prelude Therapeutics Earnings HeadlinesPrelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter Ended September 30, 2026November 16 at 11:48 AM | marketscreener.comMPrelude Q3 Loss Narrows On Lower R&D Costs; Breast Cancer Data Due In H2 2027November 16 at 11:48 AM | rttnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 16 at 1:00 AM | Behind the Markets (Ad)Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 16 at 7:01 AM | globenewswire.comPrelude Therapeutics (PRLD) Expected to Release Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comPrelude Therapeutics to Participate in the Chardan Healthcare ConferenceOctober 16, 2026 | globenewswire.comSee More Prelude Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email. Email Address About Prelude TherapeuticsPrelude Therapeutics (NASDAQ:PRLD) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments. Founded in 2016 and based in Wilmington, Delaware, Prelude conducts its drug discovery and development work in the United States. Its programs are intended to address unmet needs in oncology through targeted approaches.View Prelude Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.